Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Retained Earnings (2016 - 2025)

Fate Therapeutics' Retained Earnings history spans 14 years, with the latest figure at -$1.5 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 9.75% year-over-year to -$1.5 billion; the TTM value through Dec 2025 reached -$1.5 billion, down 9.75%, while the annual FY2025 figure was -$1.5 billion, 9.75% down from the prior year.
  • Retained Earnings reached -$1.5 billion in Q4 2025 per FATE's latest filing, down from -$1.5 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $835000.0 in Q3 2024 to a low of -$1.5 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$688.6 million, with a median of -$678.8 million recorded in 2021.
  • The largest YoY upside for Retained Earnings was 267.33% in 2024 against a maximum downside of 9320060.0% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$762000.0 in 2021, then plummeted by 143.31% to -$1.9 million in 2022, then surged by 100.81% to $15000.0 in 2023, then tumbled by 9320060.0% to -$1.4 billion in 2024, then decreased by 9.75% to -$1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for FATE's Retained Earnings are -$1.5 billion (Q4 2025), -$1.5 billion (Q3 2025), and -$1.5 billion (Q2 2025).